Amsterdam, the Netherlands <\/b>\u2013 Royal Philips<\/a> (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it ranked No. 1 among medical technology companies in the European Patent Office\u2019s (EPO) Technology Dashboard 2025. Medical technology is the most important domain for Dutch patent applications at the EPO. The ranking underscores the company\u2019s continued leadership in health technology innovation. Philips filed 676 Medtech patent applications with the EPO in 2025, including patents related to artificial intelligence (AI) across its businesses. This reflects the company\u2019s strong innovation pipeline focused on health technology solutions.<\/p>\n \u201cPhilips\u2019 continued success as a top applicant with the European Patent Office reflects the strength of our innovation engine and our focus on meaningful innovation in healthcare and self-care,\u201d said Marnix van Ginneken, Member of the Board of Management of Royal Philips. \u201cOur innovation strategy is powered by data, AI and platform-based solutions to deliver better care for more people.\u201d<\/p>\n Our customer- and consumer-centric innovation and platform-based solutions integrate hardware, software, data and AI to address clinical, operational and everyday health challenges. By securely connecting data from imaging systems, patient monitors and connected devices across care settings from hospitals to the home, Philips helps clinicians make better decisions and deliver more efficient care. Through collaborations with clinical, technology and customer partners, Philips brings new healthcare solutions to market faster and at scale.<\/p>\n Philips\u2019 innovation improved the lives of 2 billion people in 2025. By 2030, we aim to improve the lives of 2.5 billion people per year, including 400 million people in medically underserved communities.<\/p>\n Examples of Philips\u2019 recent innovations include:<\/p>\n In total, Philips contributed 1,289 European patent applications across various domains, remaining the largest Dutch applicant. The EPO ranking adds to Philips\u2019 broader recognition for innovation leadership. Earlier this year, Philips was named a Clarivate Top 100 Global Innovator<\/a> for the 13th consecutive year. In 2025, Philips invested more than 9% of sales in research and development, an industry-leading standard. Philips\u2019 intellectual property portfolio includes approximately 53,000 patent rights, 31,500 trademarks, 159,000 design rights and 3,100 domain names.<\/p>\n [1] Helium-free 3.0T MRI is Work in Progress and not available in the US or any jurisdiction. Its future availability cannot be guaranteed.<\/i><\/p>\n For further information, please contact:<\/b><\/p>\n Michael Fuchs<\/b> About Royal Philips<\/b>\n
Philips Global External Relations
Tel.: +31 614869261
E-mail: Michael.Fuchs@philips.com<\/a><\/p>\n
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people\u2019s health and well-being through meaningful innovation. Philips\u2019 patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.<\/p>\n
![](\"https:\/\/ml-eu.globenewswire.com\/media\/MjA2MzVmYWQtOTRmMi00NzEwLTg2N2ItZTFhYzlhNDkxMTg2LTEwMTQzNzUtMjAyNi0wMy0yNC1lbg==\/tiny\/Philips-International-B-V-.png\")
<\/p>\n","protected":false},"excerpt":{"rendered":"